Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.

• Jay Luly, President and CEO

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493).

(Source: Yahoo Finance)

For the second fiscal quarter ending in March 31st, 2018, Enanta reported revenues of $44 million compared to the $9 million for the same period in 2017. The increase is attributable to the royalties earned on Abbvie’s $919 million sales of hepatitis C virus regimens including MAVIRET. Research and development expenses also increased to $21.5 million in the second fiscal quarter ending in March 31st compared to the $13 million for the same period in 2017. The increase is attributable to the further progression of R&D programs in NASH, PBC, RSV, and HBV, which is showing promising clinical trial results. Net income showed a major improvement to $12.6 million from a net loss of $5.4 million for the same period in 2017.

(Source: Wikimedia Commons)

At the International Liver Congress, 2018, Enanta presented promising clinical trial results for EP-027367 and EDP-305. EP-027367 is one of several core inhibitors Enanta is developing for hepatitis B, and the data showed that in a chimeric SCID mouse model with human liver cells, EP-027367 reduced viral DNA and RNA levels up to 3.0 logs from baseline through 4 weeks of treatment. EDP-305 is Enanta’s FXR agonist in phase 2 studies for both NASH and PBC. Two of the three posters on EDP-305 focused on additional preclinical safety and efficacy data, and the third poster presented data from Enanta’s previously released Phase 1 study. Moreover, the FDA granted Enanta’s EDP-938 fast track designation for RSV, and phase 1 clinical trial is ongoing. Through such promising results in new regimen development, Enanta’s share prices have been constantly increasing for the past year.

On March 8th, I Know First’s algorithm made a bullish forecast on ENTA for a time frame of 3 months. As shown below, the signal strength was 60.13 and the predictability rating was 0.64. In accordance with eh forecasts, ENTA grew by 43.34% by June 8th. The gains of 43.34% during the 3 month period highlight I Know First’s algorithm’s accuracy.

Current I Know First subscribers received this bullish ENTA forecast on March 8th, 2018.

To subscribe today click here.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.